Search

Your search keyword '"Chiò, Adriano"' showing total 24 results
Start Over Author "Chiò, Adriano" Publisher lippincott williams & wilkins
24 results on '"Chiò, Adriano"'

1. Association of Copresence of Pathogenic Variants Related to Amyotrophic Lateral Sclerosis and Prognosis.

Author

Chiò, Adriano, Moglia, Cristina, Canosa, Antonio, Manera, Umberto, Grassano, Maurizio, Vasta, Rosario, Palumbo, Francesca, Gallone, Salvatore, Brunetti, Maura, Barberis, Marco, De Marchi, Fabiola, Dalgard, Clifton, Chia, Ruth, Mora, Gabriele, Iazzolino, Barbara, Peotta, Laura, Traynor, Bryan J., Corrado, Lucia, D'Alfonso, Sandra, and Mazzini, Letizia

Published
2023
Full Text
View/download PDF

7. Cognitive impairment across ALS clinical stages in a population-based cohort.

Author

Chio, Adriano MD, FAAN, Moglia, Cristina MD, PhD, Canosa, Antonio MD, PhD, Manera, Umberto MD, Vasta, Rosario MD, Brunetti, Maura BSc, Barberis, Marco BSc, Corrado, Lucia PhD, D'Alfonso, Sandra PhD, Bersano, Enrica MD, Sarnelli, Maria Francesca PsyD, Solara, Valentina PsyD, Zucchetti, Jean Pierre MS, Peotta, Laura PsyD, Iazzolino, Barbara PsyD, Mazzini, Letizia MD, Mora, Gabriele MD, Calvo, Andrea MD, PhD, Chiò, Adriano, and Moglia, Cristina

Published
2019
Full Text
View/download PDF

8. The multistep hypothesis of ALS revisited: The role of genetic mutations.

Author

Chiò, Adriano, Mazzini, Letizia, D'Alfonso, Sandra, Corrado, Lucia, Canosa, Antonio, Moglia, Cristina, Manera, Umberto, Bersano, Enrica, Brunetti, Maura, Barberis, Marco, Veldink, Jan H., van den Berg, Leonard H., Pearce, Neil, Sproviero, William, McLaughlin, Russell, Vajda, Alice, Hardiman, Orla, Rooney, James, Mora, Gabriele, and Calvo, Andrea

Published
2018
Full Text
View/download PDF

9. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebocontrolled, multicenter, clinical trial (RAP-ALS trial).

Author

Mandrioli, Jessica, D'Amico, Roberto, Zucchi, Elisabetta, Gessani, Annalisa, Fini, Nicola, Fasano, Antonio, Caponnetto, Claudia, Chiò, Adriano, Bella, Eleonora Dalla, Lunetta, Christian, Mazzini, Letizia, Marinou, Kalliopi, Sorarù, Gianni, de Biasi, Sara, Tartaro, Domenico Lo, Pinti, Marcello, and Cossarizza, Andrea

Published
2018
Full Text
View/download PDF

11. ATXN2 polyQ intermediate repeats are a modifier of ALS survival.

Author

Chiò, Adriano, Calvo, Andrea, Moglia, Cristina, Canosa, Antonio, Brunetti, Maura, Barberis, Marco, Restagno, Gabriella, Conte, Amelia, Bisogni, Giulia, Marangi, Giuseppe, Moncada, Alice, Lattante, Serena, Zollino, Marcella, Sabatelli, Mario, Bagarotti, Alessandra, Corrado, Lucia, Mora, Gabriele, Bersano, Enrica, Mazzini, Letizia, and D'Alfonso, Sandra

Published
2015
Full Text
View/download PDF

18. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).

Author

Mandrioli, Jessica, D'Amico, Roberto, Zucchi, Elisabetta, Gessani, Annalisa, Fini, Nicola, Fasano, Antonio, Caponnetto, Claudia, Chiò, Adriano, Dalla Bella, Eleonora, Lunetta, Christian, Mazzini, Letizia, Marinou, Kalliopi, Sorarù, Gianni, de Biasi, Sara, Lo Tartaro, Domenico, Pinti, Marcello, Cossarizza, Andrea, and RAP-ALS investigators group

Published
2018
Full Text
View/download PDF

20. Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation.

Author

Iazzolino B, Peotta L, Zucchetti JP, Canosa A, Manera U, Vasta R, Grassano M, Palumbo F, Brunetti M, Barberis M, Sbaiz L, Moglia C, Calvo A, and Chiò A

Subjects
Female, Humans, Male, Middle Aged, Mutation, Neuropsychological Tests, Amyotrophic Lateral Sclerosis complications, Amyotrophic Lateral Sclerosis genetics, C9orf72 Protein genetics, Cognition Disorders genetics
Abstract

Objective: To determine whether the neuropsychological profiles of patients with amyotrophic lateral sclerosis (ALS) with (ALSC9+) and without (ALSC9-) C9orf72 expansion are different, we administered a battery of neuropsychological tests to 741 patients with ALS (68 ALSC9+ and 673 ALSC9-) and 129 controls., Methods: The study population includes 741 patients with ALS who were consecutively diagnosed at the Turin ALS expert center in the 2010-2018 period and who underwent both cognitive/behavioral and genetic testing. Patients' neuropsychological patterns were compared (1) at the same degree of cognitive and behavioral deficit according to the revised ALS-Frontotemporal Dementia Consensus Criteria and (2) at the same level of motor impairment according to the King staging system., Results: Despite being about 7 years younger, ALSC9+ patients had significantly lower scores in tests exploring executive function and verbal memory both when classified as cognitively normal and when diagnosed in the intermediate cognitive categories. Considering the clinical perspective, ALSC9+ patients showed significantly lower scores compared to ALSC9- patients at King stage 1 and 3 in almost all the examined neuropsychological domains; at King stage 2, ALSC9+ patients were more severely affected only in the verbal memory domain. Behavioral function was comparably impaired in the 2 cohorts., Conclusions: ALSC9+ patients show a different neuropsychological profile compared to ALSC9- patients, being more impaired in executive functions and verbal memory domains at all King stages. Verbal memory emerged as a particularly vulnerable function in ALSC9+, with worse performances even when patients were still classified as cognitively normal., (© 2020 American Academy of Neurology.)

Published
2021
Full Text
View/download PDF

21. Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis.

Author

Cabras S, Calvo A, Moglia C, Chiò A, and Canosa A

Abstract

Competing Interests: A. Calvo has received a research grant from Cytokinetics. A. Chiò serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, and AveXis, and has received a research grant from Italfarmaco. The remaining authors have no conflicts of interest to declare.

Published
2020
Full Text
View/download PDF

22. ALS phenotype is influenced by age, sex, and genetics: A population-based study.

Author

Chiò A, Moglia C, Canosa A, Manera U, D'Ovidio F, Vasta R, Grassano M, Brunetti M, Barberis M, Corrado L, D'Alfonso S, Iazzolino B, Peotta L, Sarnelli MF, Solara V, Zucchetti JP, De Marchi F, Mazzini L, Mora G, and Calvo A

Subjects
Age Factors, Aged, Amyotrophic Lateral Sclerosis genetics, Cognitive Dysfunction genetics, Comorbidity, Female, Frontotemporal Dementia classification, Frontotemporal Dementia genetics, Humans, Italy epidemiology, Male, Middle Aged, Motor Disorders classification, Motor Disorders genetics, Mutation, Phenotype, Sex Factors, Amyotrophic Lateral Sclerosis classification, Amyotrophic Lateral Sclerosis epidemiology, C9orf72 Protein genetics, Cognitive Dysfunction epidemiology, Frontotemporal Dementia epidemiology, Motor Disorders epidemiology, Superoxide Dismutase-1 genetics
Abstract

Objective: To assess the determinants of amyotrophic lateral sclerosis (ALS) phenotypes in a population-based cohort., Methods: The study population included 2,839 patients with ALS diagnosed in Piemonte, Italy (1995-2015). Patients were classified according to motor (classic, bulbar, flail arm, flail leg, predominantly upper motor neuron [PUMN], respiratory) and cognitive phenotypes (normal, ALS with cognitive impairment [ALSci], ALS with behavioral impairment [ALSbi], ALSci and ALSbi combined [ALScbi], ALS-frontotemporal dementia [FTD]). Binary logistic regression analysis was adjusted for sex, age, and genetics., Results: Bulbar phenotype correlated with older age ( p < 0.0001), women were more affected than men at increasing age ( p < 0.0001), classic with younger age ( p = 0.029), men were more affected than women at increasing age ( p < 0.0001), PUMN with younger age ( p < 0.0001), flail arm with male sex ( p < 0.0001) and younger age ( p = 0.04), flail leg with male sex with increasing age ( p = 0.008), and respiratory with male sex ( p < 0.0001). C9orf72 expansions correlated with bulbar phenotype ( p < 0.0001), and were less frequent in PUMN ( p = 0.041); SOD1 mutations correlated with flail leg phenotype ( p < 0.0001), and were less frequent in bulbar ( p < 0.0001). ALS-FTD correlated with C9orf72 ( p < 0.0001) and bulbar phenotype ( p = 0.008), ALScbi with PUMN ( p = 0.014), and ALSci with older age ( p = 0.008)., Conclusions: Our data suggest that the spatial-temporal combination of motor and cognitive events leading to the onset and progression of ALS is characterized by a differential susceptibility to the pathologic process of motor and prefrontal cortices and lower motor neurons, and is influenced by age, sex, and gene variants. The identification of those factors that regulate ALS phenotype will allow us to reclassify patients into pathologically homogenous subgroups, responsive to targeted personalized therapies., (© 2020 American Academy of Neurology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results